Genmab, J&J's Janssen in Pact for HexaBody-CD38 License
June 11 2019 - 10:41AM
Dow Jones News
By Colin Kellaher
Genmab A/S (GEN.KO) on Tuesday said it signed an exclusive
world-wide license and option agreement with Johnson &
Johnson's (JNJ) Janssen Biotech Inc. to develop and commercialize
HexaBody-CD38, a human CD38 monoclonal antibody product
incorporating Genmab's HexaBody technology.
The Danish drug developer said it will fund HexaBody-CD38
research-and-development activities until completion of
proof-of-concept studies in multiple myeloma and diffuse large
B-cell lymphoma.
The company said Janssen can then acquire a world-wide license
to develop, manufacture and commercialize HexaBody-CD38 in exchange
for a $150 million option exercise fee and up to $125 million in
development milestones, along with royalties on sales.
The agreement builds on a 2012 collaboration between the
companies under which Janssen has an exclusive license to develop,
manufacture and commercialize the multiple myeloma drug
Darzalex.
If Janssen doesn't exercise its HexaBody-CD38 option, Genmab
will have the right to continue to develop and commercialize the
drug for Darzalex-resistant patients and in all other indications
except those where Darzalex is approved or being developed, Genmab
said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 11, 2019 11:26 ET (15:26 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Feb 2024 to Mar 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2023 to Mar 2024